• SDAI’s third-quarter 2026 net loss attributable to shareholders widened 30% year over year to S$ 720,612.
• Revenue climbed 49% to S$ 155,544, with contributions from distribution and retail and the new healthcare business.
• General and administrative expenses rose 30% to S$ 707,979, due mainly to higher legal and professional fees and accrued audit fees.
• The group launched its flagship anti-ageing dietary supplement, SDAI BioAge Core, in Singapore on November 6, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SDAI Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: B0GS7FQP6918AN8H) on November 12, 2026, and is solely responsible for the information contained therein.